Monoclonal antibodies with activity against components of the immune system.

Two potential vaccines against COVID-19 have entered phase I clinical trials. The EMA estimates that it may take at least a year before a vaccine against COVID-19 is ready for approval and available in sufficient quantities to meet the needs of all EU countries.

The EMA will continue to interact with developers of these medicines. Providing advice to developers on the regulatory requirements will facilitate the availability of new medicinal products as rapidly as possible, through the clinical trial setting and subsequent market.